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Abstract
Background: Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple
myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and functions.
Methods: We analyzed Treg cells in peripheral blood (n = 207) and bone marrow (n = 202) of pre-malignant and malignant
MM patients using flow cytometry. Treg cells and their subsets from MM patients and healthy volunteers were functionally
evaluated for their suppressive property. A cohort of 25 patients was analyzed for lymphocytes, CD4 T cells and Treg cells
before and after treatment with cyclophosphamide, thalidomide plus dexamethasone (CTD).
Results: We found elevated frequencies of Treg cells in newly diagnosed (P,0.01) and relapsed MM patients (P,0.0001)
compared to healthy volunteers. Also, Treg subsets including naı¨ve (P = 0.015) and activated (P = 0.036) Treg cells were
significantly increased in MM patients compared to healthy volunteers. Functional studies showed that Treg cells and their
subsets from both MM and healthy volunteers were similar in their inhibitory function. Significantly increased frequencies of
Treg cells were found in MM patients with adverse clinical features such as hypercalcemia (.10 mg/dL), decreased normal
plasma cell (#5%) count and IgA myeloma subtype. We also showed that MM patients with $5% of Treg cells had inferior
time to progression (TTP) (13 months vs. median not reached; P = 0.013). Furthermore, we demonstrated the prognostic
value of Treg cells in prediction of TTP by Cox regression analysis (P = 0.045). CTD treatment significantly reduced
frequencies of CD4 T cells (P = 0.001) and Treg cells (P = 0.018) but not Treg cells/CD4 T cells ratio compared to pre-
treatment.
Conclusions: Our study showed immune deregulation in MM patients which is evidenced by elevated level of functionally
active Treg cells and patients with increased Treg cells have higher risk of progression.
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Introduction
Multiple myeloma (MM) is a malignant plasma cell (PC)
disorder and is preceded by a pre-malignant stage known as
monoclonal gammopathy of undetermined significance (MGUS).
MGUS is characterized by lower plasma cell (PC) infiltration
(,10%) in bone marrow (BM), ,30 g/L of monoclonal protein
(M-protein) and absence of organ damage. In contrast, MM
patients are characterized by higher PC infiltration ($10%),
$30 g/L of M-protein, bone lesions and presence of organ
damage [1,2]. Immune dysfunction is an important feature of MM
leading to infections, enhancement of tumor growth and resistance
to chemotherapy. Also, decreased level of immune cells (B, CD4+
and CD8+ cells) has been documented and associated with poor
survival of MM patients [3,4]. In 2003, a study confirmed
expansion of regulatory T cells (Treg cells) in cancer patients [5].
Following this study, several studies have shown that Treg cells
were associated to impaired immune functions in solid tumors and
hematological malignancies [6,7]. In Treg cells, FoxP3 is
considered as a master regulatory molecule [8]. FoxP3 molecule
is expressed in thymus-derived Treg cells (natural Treg cells) and
peripherally induced Treg cells (CD4+CD25hi+FoxP3+) but not in
other induced Treg cells including Tr1 cells and TH3 Treg cells
[9,10]. Treg cells suppress other immune cells through contact-
dependent and independent mechanisms. Several molecules have
been reported for contact-dependent inhibition mechanism, such
as CTLA-4 (inhibits antigen presenting cells), lymphocyte activa-
tion gene 3 (induces inhibitory signal through MHC II molecules),
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granzymes (mediate lysis of conventional T cells) and CD95-
CD95L (induces apoptosis in conventional T cells) [11,12,13,14].
In contact-independent mechanism, molecules such as IL-10
(attenuates dendritic cells, converts conventional T cells into Tr1
cells), TGF-b and latency-associated peptide (induce FoxP3
expression in conventional T cells), galectin 1 (arrests cell cycle
and induces apoptosis in conventional T cells) and CD25 (adsorbs
IL-2) plays significant role in suppression [15,16,17,18,19,20].
Several studies documented peripheral blood (PB) expansion of
functionally active Treg cells in MM [21,22,23]. For the first time,
our study shows prognostic value of Treg cells in prediction of time
to progression (TTP) in MM and their association with adverse
clinical features. In addition, this study also acknowledged the
findings of previous studies in a larger cohort of patients.
In this study, we quantified and functionally evaluated Treg
cells and their subsets from pre-malignant and malignant MM
patients. Additionally, we determined the association between
MM clinical features and Treg cells. We studied the influence of
cyclophosphamide, thalidomide plus dexamethasone (CTD)
treatment on the frequencies of Treg cells. Prognostic impact of
Treg cells on MM disease progression was also analyzed.
Methods
Patients
In this study, patients were included after signing the informed
consent form according to the Helsinki protocol, and the study was
approved by University Hospital Brno institutional review board.
A total of 207 pre-malignant and malignant MM patients were
recruited for this study. Based on the diagnosis, patients were
classified into: monoclonal gammopathy of undetermined signif-
icance [MGUS-22% (45/207)], smoldering multiple myeloma
[SMM-3% (6/207)], newly diagnosed multiple myeloma [MM-
38% (79/207)], relapsed MM-31% (64/207) and patients in
remission-6% (13/207)]. PB samples were collected from all
patients but BM samples were collected only from 202 patients
due to unavailability of 5 BM samples. PB samples were also
collected from 40 healthy volunteers (HVs) as controls. Patients’
characteristics are summarized in Table 1.
A cohort of 25 newly diagnosed MM patients was analyzed for
PB total lymphocytes, CD4 T cells and Treg cells before and after
treatment by CTD. Of these 25 patients, 10 patients were treated
by autologous stem cell transplantation (SCT) after 4 cycles of
CTD induction.
Sample Preparation
Collected PB and BM samples were processed and used for
analysis within 24 hours. Both PB and BM were lysed to remove
erythrocytes using BD lysing solution (BD Biosciences, San Jose,
California) according to manufacturer’s instructions.
Fluorescence-activated Cell Sorter (FACS) Analysis and
Monoclonal Antibodies
After lysis of erythrocytes, 16106 cells were labeled with the
following fluorochrome conjugated monoclonal antibodies: phy-
coerythrin-cyanin (PE-Cy7)-CD4 (clone SK3), allophycocyanin
(APC)-CD25 (clone M-A251) plus with/without phycoerythrin
(PE)-CD127 (clone HIL-7R-M21) and (PerCP)-CD45RA (clone
MEM-56), and incubated at 4uC for 20–30 min (monoclonal
antibodies were obtained from BD Biosciences, San Jose,
California and EXBIO Prague, Czech Republic). Then, cells
were permeabilized according to eBioscience recommendations
(eBioscience, San Diego, California). Finally, cells were labeled
with FoxP3 antibody (clone PCH101) conjugated with fluorescein
isothiocyanate (FITC) from eBioscience and incubated at 4uC for
30–60 minutes. All prepared samples were measured on BD
FACSCanto II.
In order to evaluate the best sample preparation method for
screening of FoxP3 expression, we compared erythrocyte lysis and
mononuclear cell (MC) isolation (using Ficoll-Paque) methods in
5 MM patients and 5 HVs. Followed by erythrocyte lysis and
isolation of MNCs, cells were labeled similarly as described above
(Fig. S1).
Isolation of T Regulatory Cells and their Subsets
At first, T cell population was isolated from peripheral blood
mononuclear cells (PBMCs) using Pan T cell Isolation Kit II
(Miltenyi Biotech, Bergisch Gladbach, Germany). Separated T
cells were labeled with PE-Cy7-CD4 and APC-CD25. Then,
labeled cells were sorted using FACS Aria into two populations:
CD4+CD25hi+ (Treg cells) and CD4+CD252 cells (responder
cells). To isolate Treg cell subsets, purified T cell population were
labeled with PE-Cy7-CD4, APC-CD25 and PerCP-CD45RA.
Then, these labeled cells were sorted into four different
subpopulations as described previously [24,25]:
CD4+CD25+CD45RA+, CD4+CD25hi+CD45RA2,
CD4+CD25+CD45RA2 and CD4+CD252CD45RA+ (naı¨ve
CD4 T cells, responder cells). Purity of sorted cells was .96%
for all samples.
Table 1. Patients’ characteristics.
n=207
Age years; median (range) 66 (33–88)
Male/Female; n (%) 118 (57)/89 (43)
International staging system; n (%)
ISS-1 102 (49)
ISS-2 62 (30)
ISS-3 34 (17)
Unavailable 9 (4)
Myeloma subtype; n (%)
IgG 122 (59)
IgA 40 (19)
IgM 7 (4)
B-J protein 3 (1)
Others 24 (12)
Unavailable 11 (5)
b2-microglobulin mg/L; median (range) 2.81 (0.16–38.2)
Albumin g/dL; median (range) 4.0 (2.11–5.5)
Creatinine mg/dL; median (range) 0.99 (0.53–15.45)
Calcium mg/dL; median (range) 9.28 (6.96–12.8)
Hemoglobin g/dL; median (range) 11.75 (6.4–17.4)
C-reactive protein mg/L; median (range) 4.95 (0–187.1)
LDH mkat/L; median (range) 3.37 (1.57–30.89)
Serum M-protein g/L; median (range) 21.55 (0–88.5)
%of BMPCs; median (range) 2.3 (0–85.5)
% of Normal PCs; median (range) 2.3 (0–94)
Footnote: ISS, International staging system; B-J protein, Bence-Jones protein;
LDH, lactate dehydrogenase; M protein, monoclonal protein; and BMPCs, bone
marrow plasma cells.
doi:10.1371/journal.pone.0047077.t001
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Assessment of T Regulatory Cells and their Subsets
Inhibitory Function
CD4+CD252 cells were considered as responder cells and
labeled with carboxyfluorescein succinimidyl ester (CFSE).
Labeled cells were added at a concentration of 105 cells per well
into 24 well round bottom plate. Responder cells were stimulated
with anti-CD3/CD28 beads at a ratio of 1:1 and co-cultured with
equal number of autologous accessory cells (preparation of
accessory cells: CD3 T cell depleted PBMCs were isolated and
treated with mitomycin C as described previously [26]). Finally,
different concentrations of CD4+CD25hi+ cells (0:1, 1:1, 1:5, 1:10;
CD4+CD25hi+ cells: CD4+CD252 cells) were added to responders
cells in a final volume of 200–300 mL T cell expansion basal
medium containing expansion supplement, 10% of fetal calf
serum, 2 mM L-glutamine and 100 U/ml penicillin-streptomycin
(obtained from Gibco Invitrogen, Grand Island, New York and
Sigma-Aldrich, Germany). Proliferation of responder cells was
measured by CFSE dilution on flow cytometer after 4 days of
cultivation at 37uC in 5% of CO2 atmosphere. To functionally
evaluate the subsets of CD4 Treg cells including
CD4+CD25+CD45RA+, CD4+CD25hi+CD45RA2 and
CD4+CD25+CD45RA2 cells, we performed similar CFSE based
proliferation assays as described above. Isolated Treg cell subsets
were co-cultured in equal numbers with CFSE labeled naı¨ve CD4
T cells and their proliferation was assessed by CFSE dilution after
4 days of cultivation.
Cytokine Profiling
Concentration of IFN-c from the culture supernatants of
proliferation assays were measured using Human IFN-c Flex set
(BD Biosciences, San Jose, California). In brief, supernatants were
mixed with IFN-c capture beads and incubated for 1 hour. This
mixture was added with PE detection reagent and incubated for 2
hours. After incubation, the samples were washed and measured
on FACS Array.
Data Analysis
Treg cells and their subsets were analyzed from CD4+ T cells
using FACSDIVA software 6.1.2. IFN-c secretion was analyzed
using FCAP Array software.
Statistical Analysis
Data were expressed in median and range percentages for Treg
cells and their subsets. Non-parametric analyses were used
including Mann-Whitney U test and Kruskal-Wallis test to
evaluate the difference between two or more independent groups.
Figure 1. Phenotypic feature of T regulatory cells in peripheral blood and bone marrow. (A) Illustrates isotype-matched control for FoxP3
expression and phenotype of Treg cells (CD4+CD25hi+FoxP3+) from peripheral blood and bone marrow of a MM patient. (B) Histogram shows
negative/dim expression for CD127 by Treg cells compared to CD4+CD252 cells. (C) Phenotype of naı¨ve (CD4+CD45RA+FoxP3dim+), activated
(CD4+CD45RA+FoxP3hi+) and non-Treg cells (CD4+CD45RA-FoxP3dim+) from peripheral blood of a MM patient.
doi:10.1371/journal.pone.0047077.g001
Tregs Associate with Progression Risk in MM
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e47077
Association between two continuous variables was estimated by
Pearson correlation coefficients (r). TTP was calculated from start
of treatment to progression; patients who did not progress were
censored based on their last visit. Kaplan-Meier method was used
to plot survival curves and difference between curves was
calculated by Log-rank test. Cox regression analysis was used to
evaluate the prognostic effect of Treg cells on TTP. To evaluate
the difference between groups, P value of #0.05 was considered as
significant. All statistical analyses were performed with STATIS-
TICA software (9.0).
Results
Phenotypic Analysis of Treg Cells and their Subsets
Treg cell phenotype from HVs, pre-malignant and malignant
MM patients was identified as CD4+CD25hi+FoxP3+ (Fig. 1A). In
7 myeloma patients, we also screened CD127 expression on Treg
cells and results showed dim/negative expression for CD127,
which is one of the features of Treg cells (Fig. 1B). Based on the
expression of CD45RA and FoxP3 markers by CD4 T cells, three
subsets of Treg cells were identified as described previously
[24,25]: naı¨ve Treg cells (CD4+CD45RA+FoxP3dim+), activated
Treg cells (CD4+CD45RA2FoxP3hi+) and non-Treg cells
(CD4+CD45RA2FoxP3dim+) (Fig. 1C).
T Regulatory Cells and their Subsets are Elevated in
Multiple Myeloma Patients and Associated with Adverse
Clinical Features
Quantification analysis showed that PB Treg cells were
significantly elevated in patient cohort compared to HVs [5.22%
(0.89%–12.60%) vs. 3.96% (1.47%–5.90%); P,0.001]. Frequen-
cies and statistical results of PB and BM Treg cells of HVs and
patient cohort with differential clinical representations are
summarized in Fig. 2. An evaluation was done for PB Treg cells
by pooling newly diagnosed, relapsed and patients in remission
together as a MM cohort; this pooled cohort did not show
statistical significance against MGUS and SMM, while it was
highly significant against HVs (P,0.001). Unlike PB Treg cells,
significant decrease in BM Treg cells was observed in MGUS
cohort compared to pooled MM cohort [4.35% (1.10%–9.09%)
vs. 5.25% (0.58%–10.50%); P,0.01]. Both PB and BM Treg cells
Figure 2. Frequencies of peripheral blood and bone marrow T regulatory cells from pre-malignant and malignant myeloma
patients. Peripheral blood (A) and bone marrow (B) Treg cells from different patient cohorts are analyzed and evaluated statistically by Mann-
Whitney U test (P#0.05). Number of samples analyzed in each cohort is given in parentheses. Median, 25th–75th percentile and range of data are
indicated as horizontal line, box and whiskers, respectively. HVs, healthy volunteers; MGUS, monoclonal gammopathy of undetermined significance;
SMM, smoldering multiple myeloma; MM, newly diagnosed multiple myeloma; Rel, relapsed multiple myeloma; and Rem, patients in remission.
doi:10.1371/journal.pone.0047077.g002
Table 2. Association of T regulatory cells with clinical features
of multiple myeloma.
Treg cells Clinical features (n)
median % (range %)
of Treg cells P value
PB Treg cells *.10 mg/dL of calcium
(36)
5.93 (1.55–11.70) 0.004
#10 mg/dL of calcium
(167)
4.78 (0.93–12.15)
BM Treg cells *.10 mg/dL of calcium
(36)
5.88 (1.35–9.30) 0.019
#10 mg/dL of calcium
(162)
4.62 (0.62–10.46)
BM Treg cells * #5% of normal PCs
(121)
5.3 (0.6–10.4) 0.015
.5% of normal PCs (79) 4.4 (1.0–10.5)
PB Treg cells * IgA (40) 5.96 (2.74–12.05) 0.031
IgG (122) 5.04 (0.89–9.95)
BM Treg cells * IgA (39) 5.73 (2.28–10.43) 0.029
IgG (120) 4.74 (1.00–10.07)
Footnote: PB, peripheral blood; BM, bone marrow; and adverse clinical features
are marked by asterisk.
doi:10.1371/journal.pone.0047077.t002
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from MGUS cohort were significantly decreased compared to
relapsed MM cohort (P = 0.01, P = 0.0035, respectively) (Fig. 2). In
correlation analysis, frequencies of PB and BM Treg cells from
patient cohort showed strong correlation (r = 0.79; P,0.001).
Next, we analyzed Treg cell subsets including naı¨ve, activated
and non-Treg cells from PB of 5 MM patients and 5 HVs to
evaluate whether changes occurred in these subsets. Comparative
analysis showed that frequencies of naı¨ve and activated Treg cells
were significantly increased in MM patients compared to HVs
[naı¨ve Treg cells: 1.94% (1.04–2.95) vs. 0.87 (0.55–1.49);
P = 0.015, activated Treg cells: 1.02 (0.56–2.59) vs. 0.54 (0.42–
1.21); P = 0.036]. But non-Treg cells from MM patients and HVs
did not differ significantly [4.15% (2.78–5.86) vs. 3.64 (1.94–5.09);
P = 0.19].
Then, we analyzed the association between Treg cells and
clinical features of MM. Analysis showed that MM patients with
adverse clinical features, such as hypercalcemia (.10 mg/dL of
calcium), lower normal PC count (#5%) and IgA myeloma
subtype had significantly increased frequencies of Treg cells
(Table 2). Based on international staging system (ISS) of MM, we
observed insignificant increase in frequencies of PB and BM Treg
cells (data not shown).
Of note: Comparison of MC isolation and erythrocyte lysis
methods showed similar mean fluorescence intensity of FoxP3
expression in Treg cells (Fig. S1).
T Regulatory Cells and their Subsets (Naı¨ve and
Activated) are Potential Suppressors of CD4 T Cells
For functional studies of Treg cells and their subsets, highly
purified cells (.96%) were used (Fig. 3) We assessed Treg cells
(CD4+CD25hi+) from 5 newly diagnosed MM patients and 5 HVs
for their suppressive function against responder CD4 T cells
(CD4+CD252). Proliferation of CD4+CD252 cells was inhibited
in the presence of Treg cells, and inhibition was observed in dose-
dependent manner (Fig. 4A). Inhibitory activity of Treg cells from
both MM and HV cohorts was comparable (P.0.05) (Fig. 4B).
Kruskal-Wallis test showed that dose-dependent inhibition of
proliferation by Treg cells was statistically significant for MM
cohort (P,0.001) and HV cohort (P,0.001). Consistent with the
finding of proliferation inhibition by Treg cells, culture superna-
tant from MM cohort (P,0.01) and HV cohort (P,0.01) also
showed decreased concentration of IFN-c with increased numbers
of Treg cells (Fig. 4C).
Due to increase in the number of Treg subsets including naı¨ve
and activated Treg cells in MM patients, we intended to perform
functional studies to evaluate if these Treg subsets possess
suppressive function. Functional data showed that naı¨ve and
activated Treg cells from MM and HV cohorts significantly
inhibited the proliferation (Fig. 5A) and IFN-c secretion by naı¨ve
CD4 T cells compared to their absence in the proliferation assay
Figure 3. Isolation of T regulatory cells and their subsets. Isolated T lymphocytes were labeled with fluorescent conjugated monoclonal
antibodies targeting CD4 and CD25 and sorted by FACS Aria into CD4+CD25hi+ (Treg cells) and CD4+CD252 (conventional T cells). Pre- (A) and post-
sorted (B) CD4+CD25hi+ cells and CD4+CD252 cells from a MM patient is shown and purity of sorted cells is represented in percentage. Similarly, to
isolate Treg cell subsets, cells were fluorescently labeled for specific antigens (CD4, CD45RA and CD25) and sorted using FACS Aria into four
populations: CD4+CD25+CD45RA+ (naı¨ve Treg cells), CD4+CD25hi+CD45RA2 (activated Treg cells), CD4+CD25+CD45RA2 (non-Treg cells) and
CD4+CD252CD45RA+ (naı¨ve CD4 T cells). Pre- (C) and post-sorted (D) Treg cell subsets and naı¨ve CD4 T cells from a MM patient is shown and purity of
sorted cells is represented in percentage.
doi:10.1371/journal.pone.0047077.g003
Tregs Associate with Progression Risk in MM
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(Kruskal-Wallis test; P,0.05). A trend of increased inhibition of
proliferation and IFN-c secretion was observed in activated Treg
cells from MM and HV cohorts compared to naı¨ve Treg cells. In
comparative analysis, proliferation and IFN-c secretion by naı¨ve
CD4 T cells did not differ significantly between MM (n = 3) and
HVs (n = 3) either in the presence/absence of naı¨ve and activated
Treg cells (Fig. 5B, 5C). On contrary to naı¨ve and activated Treg
cells, co-culturing of non-Treg cells with naı¨ve CD4 T cells showed
that proliferation and IFN-c secretion by naı¨ve CD4 T were
similar compared to their absence. Taking these data together
clearly suggest that Treg cells and their subsets (naı¨ve and
activated Treg cells) are functional in MM patients as similar to
HVs.
Influence of Cyclophosamide, Thalidomide Plus
Dexamethasone Treatment on T Regulatory Cells
Post-CTD treatment assessment showed significant reduction in
the frequencies of CD4 T cells and Treg cells compared to pre-
treatment, whereas lymphocyte frequencies and ratio of Treg
cells/CD4 T cells were similar (Table 3). With regard to treatment
responses, $very good partial response (VGPR) was achieved in
12 patients (complete response-3/12 plus VGPR-9/12) and 13
patients achieved ,VGPR (partial response-7/13, minimal
response-1/13 and progressive disease-5/13). Patients with
$VGPR showed significant reduction in the frequencies of CD4
T cells (P = 0.031) and Treg cells (P = 0.040) after treatment
compared to pre-treatment. However, patients with ,VGPR
showed significant reduction only for CD4 T cells (P = 0.026)
(Table 4). Treg cells/CD4 T cells ratio did not differ significantly
after treatment compared to pre-treatment in patients with
$VGPR and ,VGPR.
Peripheral Blood T Regulatory Cells Predict Time to
Progression
TTP data were available only for 44/79 (56%) of newly
diagnosed MM. From 44 patients, 88% of patients were treated
with CTD, and remaining 12% of patients were treated with
different combinations including bortezomib, adriamycin plus
Figure 4. Inhibitory function of T regulatory cells. CFSE labeled CD4+CD252 cells were co-cultured with different concentration of Treg cells in
the presence of anti-CD3/CD28 beads and accessory cells. After 4 days of co-culturing, (A) based on concentration dependent manner, Treg cells
inhibited the proliferation of CFSE labeled CD4+CD252 cells which was clearly shown by the dilution of CFSE in FITC channel. In the absence of Treg
cells increased proliferation of CFSE labeled CD4+CD252 cells was observed. (B) Comparison of MM and HV Treg cells function showed similar level of
proliferation inhibition at different concentrations (proliferation/division of CD4+CD252 cells is expressed in %). (C) Similarly to proliferation inhibition,
IFN-c concentration from culture supernatant was also decreased based on Treg cell numbers (IFN-c concentration is expressed in pg/ml). Level of
IFN-c did not differ significantly between MM and HV cohorts from proliferation assays. Mann-Whitney U test was used to assess the statistical
difference between MM and HV cohorts. Statistical difference between MM and HV cohorts is indicated by P value. Median is represented by
horizontal line, and raw data from each experiment are represented by small dots and squares. CFSE, carboxyfluorescein succinimidyl ester; MM,
multiple myeloma; HV, healthy volunteer.
doi:10.1371/journal.pone.0047077.g004
Tregs Associate with Progression Risk in MM
PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e47077
dexamethasone, and cyclophosphamide plus dexamethasone. The
median follow-up of this cohort was 11 months (range: 4–18
months). A cut-off value of 5% was selected based on median
percentage of Treg cells from 44 patients. Log-rank test showed
that patients with $5% of PB Treg cells had shorter TTP
compared to patients with ,5% of PB Treg cells (13 months vs.
median not reached; P = 0.013) (Fig. 6). In univariate Cox
regression model, only PB Treg cells but not other variables (ISS
staging, b2M, albumin, calcium, creatinine, BMPCs, normal PCs,
hemoglobin, M-protein and BM Treg cells) showed prognostic
value of predicting TTP (P = 0.045) (Table 5). Unfortunately, we
were unable to perform multivariate Cox regression analysis due
to only one variable (PB Treg cells) showed significance in
univariate analysis and also no other variables were even closer to
significant value of P#0.1.
Figure 5. Inhibitory function of naı¨ve and activated T regulatory cells. Similarly, we assessed the suppressive function of naı¨ve, activated
and non-Treg cells by CFSE based proliferation assay. Naı¨ve CD4 T cells (CD4+CD252CD45RA+) were CFSE labeled and co-cultured with naı¨ve,
activated and non-Treg cells at a ratio of 1:1 in the presence of anti-CD3/CD28 beads and accessory cells. (A) Represents proliferation assay from a
MM patient. In the presence of naı¨ve and activated Treg cells in the proliferation assay, naı¨ve CD4 T cell proliferation was inhibited but not in their
absence/presence of non-Treg cells. This was clearly shown by dilution of CFSE in the FITC channel. (B) In a head to head analysis, proliferation of
naı¨ve CD4 T cells between MM patients and HVs did not differ significantly either in the presence or absence of naı¨ve and activated Treg cells in the
proliferation assay (proliferation/division of naı¨ve CD4 T cells is expressed in %). (C) Similarly, level of IFN-c secretion by naı¨ve CD4 T cells did not differ
significantly between MM and HV cohorts in the presence or absence of naı¨ve and activated Treg cells (IFN-c concentration is expressed in pg/ml).
Mann-Whitney U test was used to assess the statistical difference between MM and HV cohorts. Statistical difference between MM and HV cohorts is
indicated by P value. Median is represented by horizontal line, and raw data from each experiment are represented by small dots and squares. CFSE,
carboxyfluorescein succinimidyl ester; MM, multiple myeloma; HV, healthy volunteer.
doi:10.1371/journal.pone.0047077.g005
Table 3. Comparison of pre- and post-treatment frequencies of lymphocytes, CD4 T cells and T regulatory cells.
Cell types Pre-treatment (n =25) Post-treatment (n=25) P value
median% (range%)
Total lymphocytes 16.25 (4.33–41.36) 17.00 (6.58–52.70) 0.44
CD4 T cells 35.45 (23.00–81.33) 27.13 (2.58–54.97) 0.001
Treg cells 5.71 (3.05–9.01) 4.04 (1.67–8.63) 0.018
Ratio of Treg cells/CD4 T cells 0.17 (0.04–0.85) 0.15 (0.06–0.38) 0.31
doi:10.1371/journal.pone.0047077.t003
Tregs Associate with Progression Risk in MM
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Discussion
Treg cells play an important role in maintaining immunological
homeostasis and any imbalances leads to impaired immune
functions. It is accepted that Treg cells are expanded in
hematological and non-hematological malignancies. Increased
FoxP3 expression and Treg cell elevation are generally considered
to be poor outcome markers in various cancers, including
Hodgkin’s lymphoma, follicular lymphoma, breast cancer, gastric
malignancies, and ovarian cancers [27,28,29,30,31]. For the first
time in MM, we were able to demonstrate that increased
frequencies of Treg cells ($5%) predicted shorter TTP. Very
recently, a study also showed that high number of Treg cells from
MM patients were associated with poor survival [32]. However,
several questions are yet to be answered in MM; do tumor cells
enhance the expansion of Treg cells during progression or is
progression induced by Treg cells due to suppression of anti-tumor
responses? We believe that both processes are mutually inclusive
because several in vitro and animal model studies in other cancers
documented that tumor and tumor infiltrating cells derived factors
such as CCL2, prostaglandin 2 (PGE2), H-ferritin, indoleamine 2,
3-deoxyginase (IDO) and IL-10 recruit and enhance Treg cells in
the tumor microenvironment and thereby, increase the risk of
tumor progression [27,33,34]. In MM, a study showed that
Table 4. Comparison of pre- and post-treatment frequencies of lymphocytes, CD4 T cells and T regulatory cells in relation with
treatment response.
Patients with $ very good partial response (n =12)
Cell types Pre-treatment Post-treatment P value
median% (range%)
Total lymphocytes 14.70 (4.33–30.70 19.08 (10.60–45.69) 0.10
CD4 T cells 37.44 (23.00–60.17) 28.34 (7.46–54.97) 0.031
Treg cells 5.46 (3.59–9.01) 3.76 (1.67–7.71) 0.040
Ratio of Treg cells/CD4 T cells 0.15 (0.06–0.38) 0.14 (0.04–0.85) 0.99
Patients with , very good partial response (n =13)
Cell types Pre-treatment Post-treatment P value
median% (range%)
Total lymphocytes 17.14 (8.27–41.36) 15.57 (6.58–52.70) 0.39
CD4 T cells 34.92 (24.81–81.33) 23.53 (2.58–46.64) 0.026
Treg cells 5.71 (3.05–6.83) 4.20 (1.79–8.63) 0.22
Ratio of Treg cells/CD4 T cells 0.16 (0.06–0.27) 0.18 (0.05–0.74) 0.18
doi:10.1371/journal.pone.0047077.t004
Figure 6. Time to progression analysis according to T
regulatory cells. TTP analysis from 44 previously untreated myeloma
patients showed patients with $5% of Treg cells have shorter time for
progression. Kaplan-Meier curves demonstrate TTP according to $5%
and ,5% of peripheral blood Treg cells. TTP, Time to progression; n,
number of patients; NR, not reached.
doi:10.1371/journal.pone.0047077.g006
Table 5. Univariate Cox regression analysis for factors
influencing time to progression in multiple myeloma.
Prognostic factors
Hazard ratio
for TTP 95% CI P value
Age; $65 years 0.8 0.4–2.6 0.53
Serum M-protein; $30 g/L 1.4 0.3–6.8 0.65
b2-M; $3.5 mg/L 1.1 0.3–3.7 0.87
Albumin; ,3.5 g/L 0.8 0.2–2.5 0.64
Creatinine; $2 mg/dL 1.2 0.3–5.4 0.84
Calcium; .10 mg/dL 0.3 0.0–2.4 0.26
Hemoglobin; ,10 g/dL 0.6 0.2–2.1 0.46
BMPCs; $10% 0.7 0.2–2.7 0.61
N-PCs; .5% 2.0 0.4–9.5 0.39
ISS stage 2.4 0.3–18.6 0.41
PB Treg cells $5% 8.2 1.0–63.8 0.045
BM Treg cells $5% 2.5 0.7–9.6 0.37
Footnote: CI, confidence interval; ISS, international staging system; M protein,
monoclonal protein; b2-M, b2 microglobulin; BMPCs, bone marrow plasma cells;
N-PCs, normal plasma cells.
doi:10.1371/journal.pone.0047077.t005
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dendritic cells enhanced the expansion of Treg cells in vitro and
in vivo [35]. However, it is still unknown how Treg cells are
influenced by tumor cells/tumor microenvironment of MM
patients.
In terms of frequencies/numbers of Treg cells, we found that PB
Treg cells were expanded in MM, which was consistent with other
studies [21,22,23]. Moreover, we and others confirmed a
paradigm of decrease in Treg cells from MGUS cohort compared
to MM cohort [21,22,23]. Our report showed significantly
elevated levels of Treg cells in relapsed MM patients compared
to MGUS which was not previously demonstrated by other
studies. Some studies demonstrated that control group had
elevated frequency of Treg cells compared to MGUS and MM
cohorts [36,37]. These opposing results may be due to Treg cell
identification strategy; Prabhala et al identified Treg cells as
CD4+FoxP3+ [36], Gupta et al characterized Treg cells with the
inclusion of CD127 in their gating [37], we and Feyler et al
identified Treg cells as CD4+CD25hi+FoxP3+ [23], and Beyer et al
identified Treg cells using CD4 and CD25 markers [21]. In SMM,
our data showed insignificant decrease in PB and BM Treg cells
compared to other cohorts (HVs, MGUS, and MM). However,
due to a small number of patients in this cohort, no explanation is
conclusive. Our data showed similar level of proliferation
inhibition by Treg cells from MM patients compared to HVs,
which was corroborated by IFN-c production. This observation is
consistent with other studies [21,22,23,37] but in contrary to
Prabhala et al, who documented that Treg cells from MGUS and
MM patients have reduced inhibitory function [36]. This
difference might be due to the use of CD25 depleted whole
PBMCs as responder cells. Similarly to in vitro studies, a recent
observation showed that in MM after allogenic SCT, donor-
derived Treg cells reconstituted in BM were functional and also
enhanced the survival of transplant without graft versus host
disease [38].
Next, we focused on analysis of Treg cell subsets including,
naı¨ve and activated Treg cells in MM patients to understand their
expansion and suppressive function. Our data clearly showed that
from 5 MM patients, naı¨ve and activated Treg cells were
significantly increased compared to HVs which corroborated
previous finding [21]. Functional data revealed the ability of these
Treg subsets (naı¨ve and activated Treg cells) from MM patients to
suppress the proliferation and IFN-c secretion of naı¨ve CD4 T
cells in similar fashion to HVs. Recently, similar proliferation
inhibition by Treg cell subsets has been reported in colorectal
cancer [39]. Beyer et al TREC (T-cell receptor excision circle)
analysis showed that increased numbers of naı¨ve and memory
Treg cells in MM were due to peripherally expanded Treg cells
rather than thymus derived Treg cells [21]. Our data from MM
patients and HVs have shown that CD4 T cells which are
FoxP3dim+ and CD45 RA2 (non-Treg cells) did not possess
suppressive function. This observation is consistent with the
previous finding [25]. Taking these data together clearly suggest
that naı¨ve and activated Treg cells in MM patients are expanded
and functionally active.
We intended to screen the association between clinical features
of MM and Treg cells. Our data showed significant increase in
Treg cells from MM patients with adverse clinical features, such as
hypercalcemia, lower normal PC count and IgA myeloma
subtype. Hypercalcemia is a common adverse feature in MM
associated with bone resorption [40]. Presumably, the possible
relation between Treg cells and hypercalcemia could be explained
by the cytokine production including tumor necrosis factor (TNF-
a), vascular endothelial growth factor (VEGF), colony stimulating
factor (CSF), IL-10 and TGF-b at the tumor site which
prominently recruit osteoclasts and might also aid in expansion
of Treg cells. We suspect that this mechanism might provoke the
increase of osteoclasts and results in bone lytic lesions and
subsequently hypercalcemia occurs [23,40,41]. Patients with IgA
myeloma had significant increase in frequencies of Treg cells
compared to patients with IgG myeloma. From this finding, we
believe that IgA myeloma patients might have stronger immuno-
logical suppression than IgG myeloma patients which could also
influence survival. To support this hypothesis, several clinical data
reported that IgG myeloma patients had better prognosis than IgA
myeloma patients but difference between IgG and IgA myeloma
patients with regard to immune status/performance and functions
are yet to be revealed [42,43]. There are reports available showing
that stage dependent increases of Treg cells in MM and B-CLL
and our data also corroborate this finding but lacks statistical
significance [23,44].
In our study, patients treated by CTD showed significant
reduction of CD4 T cells and Treg cells compared to pre-
treatment. Similar results were observed in B-CLL patients who
were treated by fludarabine plus thalidomide [45]. Effects of
cyclophosphamide on Treg cells were also observed in animal
models [46,47]. We believe that reduction of CD4 T cells is due to
cytoreductive and cytotoxic effects of cyclophosphamide. Apart
from cyclophosphamide, patients were also benefited by thalido-
mide inclusion, which induces anti-tumor and immunomodulatory
effects [48]. We analyzed ratio of Treg cells/CD4 T cells to
evaluate the CTD treatment effects on Treg cells. Analysis showed
that the ratio of Treg cells/CD4 T cells did not change
significantly after treatment. This might be due to low effect of
thalidomide on Treg cells in comparison to other immunomod-
ulatory drugs (lenalidomide and pomalidomide) which was already
shown in an in vitro study [49]. These data suggest that Treg cells
are reduced due to overall reduction of CD4 T cells. Moreover,
patients with $VGPR after CTD treatment had significantly
reduced Treg cells compared to patients with,VGPR. In contrast
to our observation, Gupta et al showed that patients who
responded to therapy had increased Treg cells but not in patients
with stable and progressive disease [37]. This conflicting result
might be due to inclusion of heterogeneously treated patients in
their study.
In summary, our study shows that Treg cells and their subsets
from PB of MM patients are elevated and functional. Also, our
study demonstrates the prognostic value of Treg cells in predicting
the progression risk of myeloma patients. Post-CTD treatment
result showed reduction of Treg cells and CD4 T cells but Treg
cells/CD4 T cells ratio was similar. These findings suggest that
tumor cells in MM patients might evade immune surveillance via
increasing functionally suppressive Treg cells either in the PB or
tumor bed. Taking all these observations into consideration, we
propose that treatment targeting Treg cells might be beneficial for
MM patients.
Supporting Information
Figure S1 Comparison of FoxP3 expression between
mononuclear cell isolation method and erythrocyte lysis
method. A total of 10 cases including 5 MM and 5 HVs
peripheral blood samples were collected, and cells were prepared
for FoxP3 analysis by MC isolation method and erythrocyte lysis
method as described in methodology section. (A) and (B) represent
density plots of Treg cell analysis from a sample that was prepared
by MC isolation method and erythrocyte lysis method, respec-
tively. In all 10 cases, the expression of FoxP3 was highly similar
(no significant difference) between MC isolation method (mean6
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SD of MFI and % of Treg cells- 766.106163.10 and 5.9961.25)
and lysis method (mean6 SD of MFI and % of Treg cells-
748.806148.09 and % of Treg cells-5.9161.17). Pearsons’
correlation analysis showed very strong significant association
(r.90; P,0.0001) between MC isolation method and erythrocyte
lysis method for MFI of FoxP3 expression (C) and frequencies of
Treg cells (D). MC, mononuclear cells; MFI, mean fluorescence
intensity.
(TIF)
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